capecitabine

Overview

Oral 5-FU prodrug used in colorectal and other GI adenocarcinomas.

Evidence in the corpus

  • Listed among standard colorectal-style first-line regimens (alongside FOLFOX/FOLFIRI/FOLFIRINOX) offered to appendiceal adenocarcinoma patients; GNAS-mut predominant MAAP patients appear unlikely to benefit from such regimens given a 6% first-line response rate vs 50% in RAS-mut predominant MAAP (P=.03) PMID:36493333.
  • Component of pembrolizumab + trastuzumab + capecitabine + oxaliplatin (PTC) regimen in HER2-positive metastatic esophagogastric cancer (phase II, n=37): median PFS 13 months, ORR 89% PMID:37406106.
  • Capecitabine was among the POG-informed standard-of-care therapies administered to metastatic NEN patients in the BC Cancer POG program WGTA cohort (n=28) PMID:24326773
  • Listed as a concurrent systemic agent in reviewed SBRT trials for locally advanced PAAD; the Harvard proton-beam neoadjuvant program (50 patients, 25 Gy/5 fx + concurrent capecitabine) achieved 84% R0 resection rate in 39 resected patients, 27-month median survival, and 4.1% grade 3 acute toxicity PMID:27826200
  • Capecitabine-containing regimens were used as first-line chemotherapy in the 295-patient metastatic EGC cohort (MSK-IMPACT); HRD/LST scores did not predict platinum-based regimen response, and MSI-H patients had inferior PFS on cytotoxic therapy vs non-MSI-H PMID:29122777

Resistance mechanisms

  • GNAS-mut predominant molecular subtype of mucinous appendiceal adenocarcinoma associates with chemotherapy resistance to fluoropyrimidine-based regimens PMID:36493333.

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-15. - PMID:29122777

This page was processed by wiki-cli on 2026-05-15.